RNA Manufacturing Resources

31. mRNA-Lipid Nanoparticles Circumvent Viral Vector Limitations 6/1/2022

    Both physical and chemical nonviral gene delivery systems for ex vivo genetic modification offer advantages over viral vectors, including smaller scale production and the low risk of immunogenicity.

32. Outsourcing RNA-LNP Production: A Key To Competitive Success 3/6/2025

    Manufacturing RNA-containing LNPs demands specialized expertise. Explore some of the challenges of RNA-LNP drug manufacturing and the advantages of outsourcing RNA-LNP formulations.

33. Building A Chromatography Platform For Purification, Full Capsid Enrichment 7/18/2024

    Developing a robust chromatography platform for AAV8 purification and full capsid enrichment ensures high gene therapy product quality, addressing the challenge of empty capsid removal.

34. TFF Cassettes With 100 kDa Membranes For RNA And LNP Applications 7/3/2024

    This study showcases the performance of regenerated cellulose flat sheet membranes with a 100 kDa molecular weight cutoff for UF/DF of RNA molecules by TFF.

35. Enhanced mAb Production With High-Intensity Perfusion CHO Medium 11/27/2024

    Reach new heights in mAb production with a high-intensity perfusion CHO medium designed to support consistently high product yield and quality in continuous perfusion cultures using CHO-K1 cells.

36. Future Proof Your Process Scale Workflow 3/4/2024

    Discover how you can future-proof your process scale workflow, from starting bases to tangential flow filtration.

37. Development And Optimization Of LNP Formulations 12/6/2024

    The production of lipid nanoparticles (LNPs) is a process that demands robustness, scalability, and reproducibility. Examine the impact of key operational parameters on the efficacy of LNPs.

38. Efficient, Scalable Purification Of mRNA By Affinity Chromatography 6/7/2021

    Increasing demand for mRNA as a therapeutic product requires efficient, scalable purification methods. Here, a monolithic stationary phase is used to purify mRNA from a capping mix of Luc2 RNA.

39. Metabolite ID And Relative Quantification Of Oligonucleotides In Plasma 3/4/2022

    This technical note describes the identification, relative quantification, and structural confirmation of the chain-shortened metabolites of a phosphorothioated oligonucleotide.

40. Future-Proofing mRNA Drug Manufacturing: The Value of Continuous Improvement 4/30/2024

    With so many uncertainties permeating the mRNA market, this largely preclinical industry is still seeking answers on how to reach successful therapeutic development. Identifying optimizations, both sequence-dependent and otherwise, to enhance the manufacturing process is crucial for advancing mRNA product development, which holds vast potential to address a wide range of indications.